SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
Assays measuring SMRP (mesothelin) and HE4 (a secreted protease) in serum and other body fluids (including urine for SMRP) are likely to be clinically useful for patients with ovarian cancer, as data indicate that they complement CA125 for diagnosis and monitoring of patients. Both markers have temporal stability, as does CA125, which may be utilized to facilitate earlier diagnosis by performing longitudinal studies on high risk subjects. Preliminary data show autoantibodies to native mesothelin in some patients with ovarian carcinoma and in some healthy women. We are presently studying their relationship to the patients' clinical state to learn whether measurements of antibody levels provide information that can aid diagnosis and monitoring of treated patients. Prospective studies are needed to establish the clinical relevance of our findings.
Department of Pathology, Harborview Medical Center, University of Washington, Seattle 98104, USA. ihellstr@u.washington.edu
Ingegerd
I
Hellstrom
Karl Erik
KE
Hellstrom
D014408:Biomarkers, Tumor / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis; D030501:Epididymal Secretory Proteins / Q000032:analysis*; D005260:Female; D058851:GPI-Linked Proteins; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood* / Q000652:urine*; D000090204:Mesothelin; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D023083:beta-Defensins
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C426184:DEFB126 protein, human; D030501:Epididymal Secretory Proteins; D058851:GPI-Linked Proteins; D008562:Membrane Glycoproteins; D023083:beta-Defensins; D000090204:Mesothelin